Cyclosporine in severe ulcerative colitis refractory to steroid therapy

Simon Lichtiger*, Daniel H. Present, Asher Kornbluth, Irwin Gelernt, Joel Bauer, Greg Galler, Fabrizio Michelassi, Stephen Hanauer

*Corresponding author for this work

Research output: Contribution to journalArticle

1376 Scopus citations

Abstract

There has been no new effective drug therapy for patients with severe ulcerative colitis since corticosteroids were introduced almost 40 years ago. In an uncontrolled study, 80 percent of 32 patients with active ulcerative colitis refractory to corticosteroid therapy had a response to cyclosporine therapy. We conducted a randomized, double-blind, controlled trial in which cyclosporine (4 mg per kilogram of body weight per day) or placebo was administered by continuous intravenous infusion to 20 patients with severe ulcerative colitis whose condition had not improved after at least seven days of intravenous corticosteroid therapy. A response to therapy was defined as an improvement in a numerical symptom score (0 indicated no symptoms, and 21 severe symptoms) leading to discharge from the hospital and treatment with oral medications. Failure to respond to therapy resulted in colectomy, but some patients in the placebo group who had no response and no urgent need for surgery were subsequently treated with cyclosporine. Nine of 11 patients (82 percent) treated with cyclosporine had a response within a mean of seven days, as compared with 0 of 9 patients who received placebo (P<0.001). The mean clinical-activity score fell from 13 to 6 in the cyclosporine group, as compared with a decrease from 14 to 13 in the placebo group. All five patients in the placebo group who later received cyclosporine therapy had a response. Intravenous cyclosporine therapy is rapidly effective for patients with severe corticosteroid-resistant ulcerative colitis.

Original languageEnglish (US)
Pages (from-to)1841-1845
Number of pages5
JournalNew England Journal of Medicine
Volume330
Issue number26
DOIs
StatePublished - Jun 30 1994

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Cyclosporine in severe ulcerative colitis refractory to steroid therapy'. Together they form a unique fingerprint.

  • Cite this

    Lichtiger, S., Present, D. H., Kornbluth, A., Gelernt, I., Bauer, J., Galler, G., Michelassi, F., & Hanauer, S. (1994). Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New England Journal of Medicine, 330(26), 1841-1845. https://doi.org/10.1056/NEJM199406303302601